Evidence map›Paper›PMID 30356772›Full record

ArticleFrontiers in immunology2018

Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.

Wei Dong, Yoshita Bhide, Federica Sicca, Tjarko Meijerhof, Kate Guilfoyle, Othmar G Engelhardt, Louis Boon, Cornelis A M de Haan, George Carnell, Nigel Temperton and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. A single-shot vaccine approach for the universal influenza A vaccine candidate M2e.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 4 countries.

Wei DongDepartment of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Yoshita BhideDepartment of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Federica SiccaDepartment of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Tjarko MeijerhofDepartment of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Kate GuilfoyleNational Institute for Biological Standards and Controls, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom.
Othmar G EngelhardtNational Institute for Biological Standards and Controls, Medicines and Healthcare Products Regulatory Agency, Potters Bar, United Kingdom.
Louis BoonBioceros, Utrecht, Netherlands.
Cornelis A M de HaanVirology Division, Department of Infectious Diseases & Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.
George CarnellViral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Chatham Maritime, Kent, United Kingdom.
Nigel TempertonViral Pseudotype Unit, Medway School of Pharmacy, University of Kent, Chatham Maritime, Kent, United Kingdom.
Jacqueline de Vries-IdemaDepartment of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
David KelvinDivision of Immunology, International Institute of Infection and Immunity, Shantou University Medical College, Shantou, China.
Anke HuckriedeDepartment of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
University Medical Center Groningen · NLNational Institute for Biological Standards and Control · GBDalhousie University · CAMedway School of Pharmacy · GBPolpharma Biologics (Netherlands) · NLShantou University · CNUniversity of Groningen · NLUniversity of Kent · GBUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sequential infection with antigenically distinct influenza viruses induces cross-protective immune responses against heterologous virus strains in animal models. Here we investigated whether sequential immunization with antigenically distinct influenza vaccines can also provide cross-protection. To this end, we compared immune responses and protective potential against challenge with A(H1N1)pdm09 in mice infected sequentially with seasonal A(H1N1) virus followed by A(H3N2) virus or immunized sequentially with whole inactivated virus (WIV) or subunit (SU) vaccine derived from these viruses. Sequential infection provided solid cross-protection against A(H1N1)pdm09 infection while sequential vaccination with WIV, though not capable of preventing weight loss upon infection completely, protected the mice from reaching the humane endpoint. In contrast, sequential SU vaccination did not prevent rapid and extensive weight loss. Protection correlated with levels of cross-reactive but non-neutralizing antibodies of the IgG2a subclass, general increase of memory T cells and induction of influenza-specific CD4+ and CD8+ T cells. Adoptive serum transfer experiments revealed that despite lacking neutralizing activity, serum antibodies induced by sequential infection protected mice from weight loss and vigorous virus growth in the lungs upon A(H1N1)pdm09 virus challenge. Antibodies induced by WIV vaccination alleviated symptoms but could not control virus growth in the lung. Depletion of T cells prior to challenge revealed that CD8+ T cells, but not CD4+ T cells, contributed to cross-protection. These results imply that sequential immunization with WIV but not SU derived from antigenically distinct viruses could alleviate the severity of infection caused by a pandemic and may improve protection to unpredictable seasonal infection.

Indexed as

Adaptive ImmunityAnimalsAntibodies, NeutralizingAntibodies, ViralCross ReactionsCytokinesDisease Models, AnimalFemaleImmunizationImmunologic MemoryInfluenza A virusInfluenza VaccinesMiceOrgan SpecificityOrthomyxoviridae InfectionsSpecies SpecificityAntibodies, NeutralizingAntibodies, ViralCytokinesInfluenza VaccinesVaccines, Inactivatedantigenically distinct influenza virus strainscross-protectionimmune mechanismnon-neutralizing antibodysequential vaccination

Identifiers

PMID30356772
PMCPMC6189474
OpenAlexW2805312154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.